Compare Amphastar Pharmaceuticals Inc (AMPH) vs EHang Holdings Ltd - ADR (EH) Price & Performance

AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.

The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.

EHang Holdings (EH) trades at $5.79, up 1.76% today, with a mixed technical signal (bullish overall, bearish moving averages). The company reported Q1 2026 revenue of $418M, flat year-over-year, but net income margin remains deeply negative at -77.56%. Recent news includes the EH216-S completing Central Asia's first pilotless eVTOL flight in Kazakhstan (GlobeNewsWire, August 10, 2026), highlighting operational progress amid financial challenges.

Outlook is cautious; the stock faces significant execution risk with persistent losses and high cash burn, but analyst consensus price target of $6.97 offers modest upside. Investment opportunity hinges on successful commercialization of eVTOL technology, while risks include intense competition, regulatory hurdles, and reliance on financing to sustain operations.